Breast Cancer Genetic Test Less Cost-Effective in Actual Practice

Share this content:
Breast Cancer Genetic Test Less Cost-Effective in Actual Practice
Breast Cancer Genetic Test Less Cost-Effective in Actual Practice

FRIDAY, Jan. 19, 2018 (HealthDay News) -- A gene expression profile test to predict risk of breast cancer recurrence is less cost-effective in real-world practice as compared to ideal conditions, according to a study published online Jan. 8 in the Journal of Clinical Oncology.

Young Chandler, Ph.D., from the Lombardi Comprehensive Cancer Center in Washington, D.C., and colleagues created a simulation model to compare 25-year societal incremental costs and quality-adjusted life-years (QALYs) of community Oncotype DX use (from 2005 to 2012) versus usual care in the pretesting era (2000 to 2004).

The researchers found that 24 percent of test-eligible patients had Oncotype DX testing. Testing was higher in younger patients and in patients with stage I disease (versus stage IIA). More than three-quarters (75.3 percent) of patients with high-recurrence risk scores, and 10.2 percent of patients with low-recurrence risk scores received chemotherapy. Compared to usual care, the cost-effectiveness ratio for testing was $188,125 per QALY. Test effects on worry versus reassurance reduced the cost-effectiveness ratio to $58,431 per QALY. The cost-effectiveness ratio was lowered to $28,947 per QALY with perfect test accuracy, and $39,496 per QALY under ideal conditions.

"The differences in cost-effectiveness ratios based on community versus ideal conditions underscore the importance of considering real-world implementation when assessing the new technology," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

High Uptake, Acceptability of Rapid Fentanyl Test Strips

High Uptake, Acceptability of Rapid Fentanyl Test Strips

Significant link between receiving positive results, reporting positive change in overdose risk behavior

ACR: Walking Each Day May Cut Risk for TKA Over Five Years

ACR: Walking Each Day May Cut Risk for ...

Replacing 5 minutes of non-walking time with 5 minutes of moderate-to-vigorous walking beneficial

Short Respiratory Event Duration Ups Mortality Risk in OSA

Short Respiratory Event Duration Ups Mortality Risk in ...

Individuals with shortest-duration events had adjusted hazard ratio of 1.31 for all-cause mortality

is free, fast, and customized just for you!




Already a member?

Sign In Now »